Agilent is partnering with the Advanced Cell Therapy and Research Institute in Singapore (ACTRIS) to advance the development of cell and gene therapies over the next three years, the company said in a press release earlier this month (1).
As part of the partnership, the company will install and operate its xCELLigence real-time cell analyzer, Seahorse XF technology, and other cell analysis portfolio at the Institute, which is the largest national cell and gene therapy process development and manufacturing facility in Singapore. ACTRIS will also receive early access to Agilent’s new cell analysis platform, which will facilitate the development of cell therapies for market authorization.
Agilent has had investments in Singapore for over 20 years, with more than 600 scientists, engineers, and employees in the country. The company facilities there include a Fourth Industrial Revolution (4IR) accredited manufacturing plant, an Agilent University, and a Global Solutions Development Center where its local scientists develop integrated end-to-end workflow methods and novel applications for projects.
(1) Agilent. Agilent and ACTRIS Partner to Accelerate Cell and Gene Therapy in Singapo nnnnre.Agilent 2023. https://www.agilent.com/about/newsroom/presrel/2023/04sep-ca23035.html(accessed 2023-09-11)
USP CEO Discusses Quality and Partnership in Pharma
December 11th 2024Ronald Piervincenzi, chief executive officer of the United States Pharmacoepia, focused on how collaboration and component quality can improve worldwide pharmaceutical production standards during a lecture at the Eastern Analytical Symposium (EAS) last month.
RAFA 2024: Giorgia Purcaro on Multidimensional GC for Mineral Oil Hydrocarbon Analysis
November 27th 2024Giorgia Purcaro from the University of Liège was interviewed at RAFA 2024 by LCGC International on the benefits of modern multidimensional GC methods to analyze mineral oil aromatic hydrocarbons (MOAH) and mineral oil saturated hydrocarbons (MOSH).